<DOC>
	<DOC>NCT02019056</DOC>
	<brief_summary>The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease and Alcoholic Hepatitis.</brief_summary>
	<brief_title>Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Hepatitis, Alcoholic</mesh_term>
	<mesh_term>Fatty Liver, Alcoholic</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>â€¢Patients over 18, under 70 years of age The chronic alcohol intake patients Current the heavy drinker over 3month, Day the average alcohol consumption Male&gt;=60g, Female&gt;=40mg yGTP increase Male&gt;=75, Female&gt;=35 Over 1.5 ratio of AST to ALT Patients who have chronoc alcohol disease Patients who have liver disease with the cause different with the alcohol except Patients who have pyridoxine allergy or history Patients who are judged by investigator that participation of the study is difficult due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor, serious metabolic disease, severe renal disease, severe pulmonary disease, severe cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease and etc Patients taking other investigational product within 90 days prior to the participation in the study. Patients who has been taken any medications that could affect the treatment : hypoglycemic agents, colchicine, penicillamine, corticosteroids, ursodeoxycholic acid, pentoxifylline, lontterm use of NSAIDs, statins, neuroleptics, anti convulsive medications, highdose acetaminophen(&gt;=2.5g/day) Patients who have received treatment that may affect liver function within 1 month prior to the participation in the study Patient who considered ineligible for participation in the study as Investigator's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>